Search

Your search keyword '"Catalano, Paul J."' showing total 455 results
Start Over Author "Catalano, Paul J." Publication Type Academic Journals
455 results on '"Catalano, Paul J."'

2. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field

Author

Liu, Kevin X., Shaaban, Sherif G., Chen, Jie Jane, Bagatell, Rochelle, Lerman, Benjamin J., Catalano, Paul J., DuBois, Steven G., Shusterman, Suzanne, Ioakeim-Ioannidou, Myrsini, Yock, Torunn I., Shamberger, Robert C., Mattei, Peter, Vu, Lan, Elhalawani, Hesham, Dusenbery, Kathryn E., Vo, Kieuhoa T., Huang, Mary S., Friedmann, Alison M., Diller, Lisa R., Marcus, Karen J., MacDonald, Shannon M., Terezakis, Stephanie A., Braunstein, Steve E., Hill-Kayser, Christine E., and Haas-Kogan, Daphne A.

Published
2024
Full Text
View/download PDF

3. Automated temporalis muscle quantification and growth charts for children through adulthood

Author

Zapaishchykova, Anna, Liu, Kevin X., Saraf, Anurag, Ye, Zezhong, Catalano, Paul J., Benitez, Viviana, Ravipati, Yashwanth, Jain, Arnav, Huang, Julia, Hayat, Hasaan, Likitlersuang, Jirapat, Vajapeyam, Sridhar, Chopra, Rishi B., Familiar, Ariana M., Nabavidazeh, Ali, Mak, Raymond H., Resnick, Adam C., Mueller, Sabine, Cooney, Tabitha M., Haas-Kogan, Daphne A., Poussaint, Tina Y., Aerts, Hugo J.W.L., and Kann, Benjamin H.

Published
2023
Full Text
View/download PDF

7. Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes.

Author

Xu, Wenxin, Gaborieau, Valerie, Niman, Samuel M., Mukeria, Anush, Liu, Xiaowen, Maremanda, Krishna P., Takakura, Ayumi, Zaridze, David, Freedman, Matthew L., Xie, Wanling, McDermott, David F., Choueiri, Toni K., Catalano, Paul J., Sabbisetti, Venkata, Bonventre, Joseph V., Pierorazio, Phillip M., Singla, Nirmish, Brennan, Paul, and Bhatt, Rupal S.

Published
2024
Full Text
View/download PDF

13. Minimally Invasive Esophagectomy

Author

Luketich, James D, Pennathur, Arjun, Franchetti, Yoko, Catalano, Paul J, Swanson, Scott, Sugarbaker, David J, De Hoyos, Alberto, Maddaus, Michael A, Nguyen, Ninh T, Benson, Al B, and Fernando, Hiran C

Subjects
Patient Safety, Clinical Research, Rare Diseases, Cancer, Clinical Trials and Supportive Activities, Digestive Diseases, Evaluation of treatments and therapeutic interventions, Management of diseases and conditions, 6.4 Surgery, 7.3 Management and decision making, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Anastomotic Leak, Comorbidity, Critical Care, Esophageal Neoplasms, Esophagectomy, Feasibility Studies, Female, Follow-Up Studies, Humans, Incidence, Laparoscopy, Length of Stay, Male, Middle Aged, Neoplasm Recurrence, Local, Operative Time, Postoperative Complications, Prospective Studies, Survival Rate, Thoracoscopy, Treatment Outcome, esophagectomy, esophageal resection, MIE, minimally invasive, surgical procedures, Medical and Health Sciences, Surgery
Abstract

ObjectiveThe primary aim of this trial was to assess the feasibility of minimally invasive esophagectomy (MIE) in a multi-institutional setting.BackgroundEsophagectomy is an important, potentially curative treatment for localized esophageal cancer, but is a complex operation. MIE may decrease the morbidity and mortality of resection, and single-institution studies have demonstrated successful outcomes with MIE.MethodsWe conducted a multicenter, phase II, prospective, cooperative group study (coordinated by the Eastern Cooperative Oncology Group) to evaluate the feasibility of MIE. Patients with biopsy-proven high-grade dysplasia or esophageal cancer were enrolled at 17 credentialed sites. Protocol surgery consisted of either 3-stage MIE or Ivor Lewis MIE. The primary end point was 30-day mortality. Secondary end points included adverse events, duration of hospital-stay, and 3-year outcomes.ResultsProtocol surgery was completed in 95 of the 104 patients eligible for the primary analysis (91.3%). The 30-day mortality in eligible patients who underwent MIE was 2.1%; perioperative mortality in all registered patients eligible for primary analysis was 2.9%. Median intensive care unit and hospital stay were 2 and 9 days, respectively. Grade 3 or higher adverse events included anastomotic leak (8.6%), acute respiratory distress syndrome (5.7%), pneumonitis (3.8%), and atrial fibrillation (2.9%). At a median follow-up of 35.8 months, the estimated 3-year overall survival was 58.4% (95% confidence interval: 47.7%-67.6%). Locoregional recurrence occurred in only 7 patients (6.7%).ConclusionsThis prospective multicenter study demonstrated that MIE is feasible and safe with low perioperative morbidity and mortality and good oncological results. This approach can be adopted by other centers with appropriate expertise in open esophagectomy and minimally invasive surgery.

Published
2015

14. Minimally invasive esophagectomy: results of a prospective phase II multicenter trial-the eastern cooperative oncology group (E2202) study.

Author

Luketich, James D, Pennathur, Arjun, Franchetti, Yoko, Catalano, Paul J, Swanson, Scott, Sugarbaker, David J, De Hoyos, Alberto, Maddaus, Michael A, Nguyen, Ninh T, Benson, Al B, and Fernando, Hiran C

Subjects
Humans, Esophageal Neoplasms, Neoplasm Recurrence, Local, Postoperative Complications, Laparoscopy, Thoracoscopy, Treatment Outcome, Critical Care, Length of Stay, Esophagectomy, Incidence, Survival Rate, Follow-Up Studies, Prospective Studies, Feasibility Studies, Comorbidity, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Male, Anastomotic Leak, Operative Time, esophagectomy, esophageal resection, MIE, minimally invasive, surgical procedures, Neoplasm Recurrence, Local, and over, Surgery, Medical and Health Sciences
Abstract

ObjectiveThe primary aim of this trial was to assess the feasibility of minimally invasive esophagectomy (MIE) in a multi-institutional setting.BackgroundEsophagectomy is an important, potentially curative treatment for localized esophageal cancer, but is a complex operation. MIE may decrease the morbidity and mortality of resection, and single-institution studies have demonstrated successful outcomes with MIE.MethodsWe conducted a multicenter, phase II, prospective, cooperative group study (coordinated by the Eastern Cooperative Oncology Group) to evaluate the feasibility of MIE. Patients with biopsy-proven high-grade dysplasia or esophageal cancer were enrolled at 17 credentialed sites. Protocol surgery consisted of either 3-stage MIE or Ivor Lewis MIE. The primary end point was 30-day mortality. Secondary end points included adverse events, duration of hospital-stay, and 3-year outcomes.ResultsProtocol surgery was completed in 95 of the 104 patients eligible for the primary analysis (91.3%). The 30-day mortality in eligible patients who underwent MIE was 2.1%; perioperative mortality in all registered patients eligible for primary analysis was 2.9%. Median intensive care unit and hospital stay were 2 and 9 days, respectively. Grade 3 or higher adverse events included anastomotic leak (8.6%), acute respiratory distress syndrome (5.7%), pneumonitis (3.8%), and atrial fibrillation (2.9%). At a median follow-up of 35.8 months, the estimated 3-year overall survival was 58.4% (95% confidence interval: 47.7%-67.6%). Locoregional recurrence occurred in only 7 patients (6.7%).ConclusionsThis prospective multicenter study demonstrated that MIE is feasible and safe with low perioperative morbidity and mortality and good oncological results. This approach can be adopted by other centers with appropriate expertise in open esophagectomy and minimally invasive surgery.

Published
2015

15. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck

Author

Margalit, Danielle N., Haddad, Robert I., Tishler, Roy B., Chau, Nicole G., Schoenfeld, Jonathan D., Bakst, Richard L., Misiukiewicz, Krzysztof J., Gupta, Vishal, Posner, Marshall, Hanna, Glenn J., Mahmood, Umair, Rawal, Bhupendra, Catalano, Paul J., Rath, Lynda, Bacay, Alyssa, McHugh, Patricia, and Rabinowits, Guilherme

Published
2019
Full Text
View/download PDF

19. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.

Author

El Ahmar, Nourhan, Matar, Sayed, Jegede, Opeyemi, Nabil Laimon, Yasmin, Savla, Varunika, Bagheri Sheshdeh, Aseman, Denize, Thomas, Mohanna, Razan Assaad, Choueiri, Toni K., Catalano, Paul J., Braun, David A., Haas, Naomi B., Hammers, Hans J., Bilen, Mehmet Asim, Stein, Mark N., Sosman, Jeffrey A., Wu, Catherine J., McDermott, David F., Atkins, Michael B., and Signoretti, Sabina

Published
2024
Full Text
View/download PDF

21. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma

Author

Schoenfeld, Jonathan D., Gjini, Evisa, Rodig, Scott J., Tishler, Roy B., Rawal, Bhupendra, Catalano, Paul J., Uppaluri, Ravindra, Haddad, Robert I., Hanna, Glenn J., Chau, Nicole G., Rabinowits, Guilherme, Lorch, Jochen, Jo, Vickie Y., Krane, Jeffrey F., Goguen, Laura A., Annino, Donald J., Abdelrahman, Sara, Lipschitz, Mikel, and Margalit, Danielle N.

Published
2018
Full Text
View/download PDF

22. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation

Author

Cagney, Daniel N., Martin, Allison M., Catalano, Paul J., Reitman, Zachary J., Mezochow, Gabrielle A., Lee, Eudocia Q., Wen, Patrick Y., Weiss, Stephanie E., Brown, Paul D., Ahluwalia, Manmeet S., Arvold, Nils D., Tanguturi, Shyam K., Haas-Kogan, Daphne A., Alexander, Brian M., Redig, Amanda J., and Aizer, Ayal A.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results